Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Globo-H-GM2-sTn-TF-Tn-KLH
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Globo-H-GM2-sTn-TF-Tn-KLH is a synthetic unimolecular pentavalent cancer vaccine developed by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of epithelial ovarian, fallopian tube, and peritoneal cancers. The vaccine consists of five tumor-associated carbohydrate antigens (TACAs)—Globo-H, GM2 (ganglioside M2), sTn (sialyl-Tn), TF (Thomsen-Friedenreich antigen), and Tn antigen—chemically synthesized on a single peptide backbone and conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein. Administered with the immunological adjuvant QS-21, the vaccine is designed to induce a polyvalent antibody response against multiple targets overexpressed on the surface of ovarian cancer cells, potentially overcoming tumor heterogeneity and antigen loss.
- Other names
- Unimolecular pentavalent vaccinePentavalent carbohydrate vaccineGlobo-H-GM2-sTn-TF-Tn-KLH conjugateGlobo-H-GM-2-sTn-TF-Tn-KLH conjugateGlobo-H-GM 2-sTn-TF-Tn-KLH conjugate
02
Targets
GM2 (Ganglioside GM2)Globo-HTn (Tn antigen)STn-MUC1 (Sialyl-Tn-MUC1)TF antigen (Thomsen-Friedenreich antigen)
Beyond the preview
Go deeper on Globo-H-GM2-sTn-TF-Tn-KLH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Globo-H-GM2-sTn-TF-Tn-KLH.